Scinai Immunotherapeutics Ltd

SCNI

0.550USD

-0.051-8.44%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

Scinai Immunotherapeutics Ltd's Score

Industry at a Glance

Industry Ranking

216 / 391

Overall Ranking

455 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Scinai Immunotherapeutics Ltd Highlights

StrengthsRisks

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Growing

The company is in a growing phase, with the latest annual income totaling USD 658.00K.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 0.05, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 166.27K shares, increasing 32.35% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.81.

Analyst Rating

Based on 0 analysts

--

Current Rating

--

Target Price

--

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Scinai Immunotherapeutics Ltd is 5.86, ranking 312 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.69

Change

0.17



Financials

5.90

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.17

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.18

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.09

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Scinai Immunotherapeutics Ltd is 7.40, ranking 124 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.05, which is 1126.44% below the recent high of 0.66 and 291.62% above the recent low of -0.10.

Score

Industry at a Glance

Previous score

7.40

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 216/391

Relevant data have not been disclosed by the company yet.

No earnings forecast score is currently available for Scinai Immunotherapeutics Ltd. The Biotechnology & Medical Research industry's average is 8.07.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Scinai Immunotherapeutics Ltd is 5.28, ranking 320 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.92 and the support level at 0.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.29

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RK Stone Miami, LLC

200.00K

--

Stone (Daniel E)

64.20K

+2.88%

LCK JNK 1 LLC

80.76K

--

Armistice Capital LLC

44.80K

--

Citadel Advisors LLC

28.63K

+146.83%

Sabby Management, LLC

29.05K

--

Abalone Asset Management Ltd.

42.54K

+136.35%

Reichman (Amir)

8.08K

+236.54%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Scinai Immunotherapeutics Ltd is 1.75, ranking 280 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.97. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Scinai Immunotherapeutics Ltd

SCNI

4.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment